TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35486027

Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma (PRP)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Mucosal Advancement Flap (MAF)
Number of subjects: 96
Study: 33369680

Group type: EXPERIMENTAL
Intervention: Behavioural‐based physical activity intervention (12 weeks, 8 face-to-face sessions, 12 weekly phone calls, Fitbit tracking)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Standard care (sign-posting to fatigue websites)
Number of subjects: 134
Study: 34473238

Group type: EXPERIMENTAL
Intervention: Novel digital ostectomy template (DOT) in Group B
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional digital ostectomy template (DOT) in Group A
Number of subjects: 20
Study: 37682422

Group type: EXPERIMENTAL
Intervention: Tralokinumab 300 mg every 2 weeks (q2w)
Number of subjects: 1596

Group type: EXPERIMENTAL
Intervention: Tralokinumab 300 mg every 4 weeks (q4w)
Number of subjects: 1596

Group type: COMPARATOR
Intervention: Placebo (Tralokinumab withdrawal)
Number of subjects: 1596

Group type: EXPERIMENTAL
Intervention: Tralokinumab treatment beyond Week 16 to Week 52
Number of subjects: 1596
Study: 33483226

Group type: EXPERIMENTAL
Intervention: Paclitaxel-Eluting Balloon Angioplasty (DCB)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Plain-Balloon Angioplasty (PTA)
Number of subjects: 120
Study: 32542818

Group type: EXPERIMENTAL
Intervention: 500 mg/day curcuminoids co‐administered with 5 mg/day piperine for 7 days
Number of subjects: 62

Group type: COMPARATOR
Intervention: Matched placebo for 7 days
Number of subjects: 62
Study: 32406798

Group type: EXPERIMENTAL
Intervention: Hippotherapy intervention (12 weekly sessions)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Usual therapy only (Control)
Number of subjects: 13
Study: 32594273

Group type: EXPERIMENTAL
Intervention: Cystine and theanine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control
Number of subjects: 28
Study: 34201686

Group type: EXPERIMENTAL
Intervention: Bee Venom Acupuncture (BVA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) - loxoprofen (180 mg daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined treatment of BVA and NSAIDs
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 33638690

Group type: EXPERIMENTAL
Intervention: Low-load blood flow restriction (LLBFR) resistance training (n=10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (n=10)
Number of subjects: 20
Study: 33262523

Group type: EXPERIMENTAL
Intervention: Branching evolution pattern
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Acquisition of gain(1q) at relapse
Number of subjects: 178
Study: 35239083

Group type: EXPERIMENTAL
Intervention: Navigator ACT (Acceptance and Commitment Therapy group intervention)
Number of subjects: 94
Study: 32246686

Group type: EXPERIMENTAL
Intervention: Caries-free (CF) group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Early childhood caries (ECC) group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Severe early childhood caries (S-ECC) group
Number of subjects: 120
Study: 34506241

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.4 mg insert
Number of subjects: 20

Group type: COMPARATOR
Intervention: Prednisolone acetate 1% taper
Number of subjects: 20
Study: 35616272

Group type: EXPERIMENTAL
Intervention: EE/DRSP plus Orlistat
Number of subjects: 66

Group type: COMPARATOR
Intervention: EE/DRSP alone
Number of subjects: 66
Study: 35001412

Group type: EXPERIMENTAL
Intervention: Soticlestat 100-400 mg QD
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Soticlestat 600 mg QD
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Soticlestat 300 mg BID
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 35642031

Group type: EXPERIMENTAL
Intervention: Community-based health insurance (CBHI)
Number of subjects: 340
Study: 32053813

Group type: EXPERIMENTAL
Intervention: MDD group (26 patients)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Normal group (23 subjects)
Number of subjects: 49
Study: 35481934

Group type: EXPERIMENTAL
Intervention: Dibutyl phthalate (DBP) exposure for 3 hours
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control air exposure for 3 hours
Number of subjects: 16
Study: 33951173

Group type: EXPERIMENTAL
Intervention: Hemostatic pack (HP) application
Number of subjects: 25

Group type: COMPARATOR
Intervention: No hemostatic measures (Control)
Number of subjects: 25
Study: 34387216

Group type: EXPERIMENTAL
Intervention: Facilitated tucking with morphine (0.05‐mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care with morphine (0.05‐mg/kg)
Number of subjects: 60
Study: 34862875

Group type: EXPERIMENTAL
Intervention: Danhong injection
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (routine treatment)
Number of subjects: 100
Study: 33991066

Group type: EXPERIMENTAL
Intervention: Trihexyphenidyl (TP)
Number of subjects: 34
Study: 32321881

Group type: EXPERIMENTAL
Intervention: Group 3 (persistent dysfunction)
Number of subjects: 29133

Group type: EXPERIMENTAL
Intervention: Group 2 (escalating dysfunction)
Number of subjects: 29133

Group type: COMPARATOR
Intervention: Group 1 (no dysfunction)
Number of subjects: 29133
Study: 35438450

Group type: EXPERIMENTAL
Intervention: Late booster
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Early booster
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study: 32662540

Group type: EXPERIMENTAL
Intervention: Brodalumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 0
Study: 35225519

Group type: EXPERIMENTAL
Intervention: 0.3% nepafenac eye drops once daily for 4 weeks
Number of subjects: 2

Group type: COMPARATOR
Intervention: 0.1% nepafenac eye drops three times/day for 4 weeks
Number of subjects: 2
Study: 32585278

Group type: EXPERIMENTAL
Intervention: Topical terbinafine 10% solution (MOB-015)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study: 32025254

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT), 8 sessions of 60 minutes each
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 36198385

Group type: EXPERIMENTAL
Intervention: Probiotic Bacillus clausii UBBC‐07
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35993161

Group type: EXPERIMENTAL
Intervention: BFKB8488A
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: BFKB8488A (medium exposure)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: BFKB8488A (high exposure)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: BFKB8488A (NAFLD patients, low exposure)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: BFKB8488A (NAFLD patients, medium exposure)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: BFKB8488A (NAFLD patients, high exposure)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo (NAFLD patients)
Number of subjects: 153
Study: 33963420

Group type: EXPERIMENTAL
Intervention: MBSR(BC)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 322
Study: 32933950

Group type: EXPERIMENTAL
Intervention: Weight-based insulin titration algorithm
Number of subjects: 575

Group type: COMPARATOR
Intervention: Glucose-based insulin titration algorithm
Number of subjects: 575
Study: 34238679

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 50

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 50
Study: 33151971

Group type: EXPERIMENTAL
Intervention: Dietary and physical activity intervention (low glycaemic index diet plus physical activity)
Number of subjects: 557

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 557
Study: 37353151

Group type: EXPERIMENTAL
Intervention: Simulation-based just-in-time training (JITT, short video and simulation)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Video training (5-minute video)
Number of subjects: 65
Study: 33580103

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplement (10 mg iron, 10 mg zinc, 400 µg vitamin A)
Number of subjects: 347

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 347
Study: 32199882

Group type: EXPERIMENTAL
Intervention: Ustekinumab (anti-IL-12/IL-23 blockade) as induction and maintenance therapy
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study: 37602984

Group type: EXPERIMENTAL
Intervention: AHME intervention (social health insurance, social franchising, SafeCare quality-of-care certification programme, business support)
Number of subjects: 8241

Group type: EXPERIMENTAL
Intervention: AHME intervention
Number of subjects: 8241

Group type: EXPERIMENTAL
Intervention: Standardized patient (SP) experiment
Number of subjects: 8241
Study: 33581684

Group type: EXPERIMENTAL
Intervention: LiFE4D
Number of subjects: 12

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 12
Study: 32956262

Group type: EXPERIMENTAL
Intervention: Unilateral strength training (UL; n = 7)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Bilateral strength training (BL; n = 8)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both training groups
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Unilateral eyes open and bilateral stance tasks
Number of subjects: 15
Study: 33880753

Group type: EXPERIMENTAL
Intervention: Parent-adolescent communication and parental depressive symptomatology as mediators
Number of subjects: 456
Study: 34555068

Group type: EXPERIMENTAL
Intervention: IMT+ET
Number of subjects: 32

Group type: COMPARATOR
Intervention: ET
Number of subjects: 32
Study: 32854756

Group type: EXPERIMENTAL
Intervention: Hwangryunhaedok-tang (HHT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo granules
Number of subjects: 30
Study: 35914215

Group type: EXPERIMENTAL
Intervention: Remote patient monitoring with health coaching (N=188)
Number of subjects: 375

Group type: COMPARATOR
Intervention: Wait-list usual care (n=187)
Number of subjects: 375
Study: 34023556

Group type: EXPERIMENTAL
Intervention: Mobile-based education
Number of subjects: 160

Group type: COMPARATOR
Intervention: Booklet-based education
Number of subjects: 160
Study: 35385209

Group type: EXPERIMENTAL
Intervention: 320 mg of anthocyanins (bilberry trihydroxy‐type)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 320 mg of anthocyanins (black rice dihydroxy‐type)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 34131749

Group type: EXPERIMENTAL
Intervention: Radiomics-based classifier model using 21 imaging and clinical features
Number of subjects: 266

Group type: COMPARATOR
Intervention: Human experts using imaging and clinical features
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Radiomics-based classifier
Number of subjects: 266

Group type: COMPARATOR
Intervention: Expert humans
Number of subjects: 266
Study: 32460997

Group type: EXPERIMENTAL
Intervention: Multi-day Methotrexate (MTX)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Pulse Actinomycin-D (ACT-D)
Number of subjects: 57
Study: 35238767

Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy (WBC) - 6 applications in 14 days at -130°C for 3 min
Number of subjects: 56

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy (WBC)
Number of subjects: 56
Study: 35710926

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) on days 0, 3, 7, 14, and every 2 weeks thereafter (Group A)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) every 3 weeks (Group B)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control sides (not receiving LLLT)
Number of subjects: 20
Study: 35864005

Group type: EXPERIMENTAL
Intervention: Daily motivational messages sent via SMS for 21 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: No motivational messages
Number of subjects: 60
Study: 33470654

Group type: EXPERIMENTAL
Intervention: Neurally controlled pressure support (PSN)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional pressure support ventilation (PSP)
Number of subjects: 24
Study: 32570152

Group type: EXPERIMENTAL
Intervention: Intravenous labetalol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral nifedipine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison between labetalol and nifedipine
Number of subjects: 30
Study: 35157622

Group type: EXPERIMENTAL
Intervention: Trauma-informed collaborative care (TICC)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 42
Study: 34054116

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation and deep breathing exercises
Number of subjects: 169
Study: 32432339

Group type: EXPERIMENTAL
Intervention: BRV 100 mg/d
Number of subjects: 1160

Group type: EXPERIMENTAL
Intervention: BRV 200 mg/d
Number of subjects: 1160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1160
Study: 35698087

Group type: EXPERIMENTAL
Intervention: Collaborative care model
Number of subjects: 2486

Group type: COMPARATOR
Intervention: Enhanced standard treatment
Number of subjects: 2486
Study: 33211380

Group type: EXPERIMENTAL
Intervention: Minimally processed parsley samples
Number of subjects: 100
Study: 35997125

Group type: EXPERIMENTAL
Intervention: V114 vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: PCV7
Number of subjects: 0

Group type: COMPARATOR
Intervention: PCV13
Number of subjects: 0
Study: 33675838

Group type: EXPERIMENTAL
Intervention: 20 mg d-amphetamine
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 35140804

Group type: EXPERIMENTAL
Intervention: Treadmill exercise training program
Number of subjects: 110

Group type: COMPARATOR
Intervention: Diabetic control group (no intervention)
Number of subjects: 110
Study: 35071591

Group type: EXPERIMENTAL
Intervention: Iron proteinsuccinylate oral solution combined with vitamin A and D drops
Number of subjects: 124

Group type: COMPARATOR
Intervention: Iron proteinsuccinylate oral solution (1.5 mL/kg)
Number of subjects: 124
Study: 32978546

Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 414

Group type: COMPARATOR
Intervention: Conventional health education
Number of subjects: 414
Study: 33688827

Group type: EXPERIMENTAL
Intervention: Self-report screening for sleep apnea
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Self-report screening for insomnia disorder
Number of subjects: 420

Group type: COMPARATOR
Intervention: Medical record diagnosis of insomnia
Number of subjects: 420

Group type: COMPARATOR
Intervention: Medical record diagnosis of sleep apnea
Number of subjects: 420

Group type: COMPARATOR
Intervention: Medical record diagnosis of both conditions
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Overall screening for sleep disorders
Number of subjects: 420
Study: 35474389

Group type: EXPERIMENTAL
Intervention: Maternal SNP rs12785878 (DHCR7)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Offspring SNP rs2282679 (GC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maternal SNP rs1074657
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maternal SNP rs613897
Number of subjects: 0

Group type: COMPARATOR
Intervention: Offspring SNP rs1074657
Number of subjects: 0

Group type: COMPARATOR
Intervention: Offspring SNP rs613897
Number of subjects: 0
Study: 34301225

Group type: EXPERIMENTAL
Intervention: Six-minute walking distance
Number of subjects: 909

Group type: EXPERIMENTAL
Intervention: Physical activity (PA)
Number of subjects: 909

Group type: EXPERIMENTAL
Intervention: Aerobic component of physical performance
Number of subjects: 909

Group type: EXPERIMENTAL
Intervention: Other physical performance components
Number of subjects: 909
Study: 33345961

Group type: EXPERIMENTAL
Intervention: Prenatal aerobic exercise (150 minutes of supervised, moderate-intensity aerobic exercise per week)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Nonexercising group (150 minutes per week of light stretching and relaxation breathing techniques)
Number of subjects: 133
Study: 33928372

Group type: EXPERIMENTAL
Intervention: Digital cognitive aid (CA) used during simulations
Number of subjects: 34

Group type: COMPARATOR
Intervention: No digital cognitive aid (CA) used during simulations
Number of subjects: 34
Study: 33830181

Group type: COMPARATOR
Intervention: Polygenic risk score derived from HM vs emmetropia GWAS
Number of subjects: 51841

Group type: COMPARATOR
Intervention: Polygenic risk score derived from LM vs emmetropia GWAS
Number of subjects: 51841

Group type: COMPARATOR
Intervention: Polygenic risk score derived from hyperopia vs emmetropia GWAS
Number of subjects: 51841

Group type: COMPARATOR
Intervention: Polygenic risk score derived from LM vs hyperopia GWAS
Number of subjects: 51841
Study: 36170042

Group type: EXPERIMENTAL
Intervention: Playful situational game (PSG) intervention
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (no PSG)
Number of subjects: 116
Study: 36160428

Group type: EXPERIMENTAL
Intervention: Active insula deep rTMS (10 Hz)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham insula deep rTMS
Number of subjects: 50
Study: 34775240

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg two times daily + Mebeverine 135 mg three times daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Mebeverine 135 mg three times daily
Number of subjects: 50
Study: 34149014

Group type: EXPERIMENTAL
Intervention: Oral appliance therapy for obstructive sleep apnoea (1-2 months duration)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Oral appliance therapy for obstructive sleep apnoea
Number of subjects: 152
Study: 35780813

Group type: EXPERIMENTAL
Intervention: COVID‐19 convalescent plasma (n = 487)
Number of subjects: 974

Group type: COMPARATOR
Intervention: Placebo (n = 473)
Number of subjects: 974

Group type: COMPARATOR
Intervention: Placebo (n = 465)
Number of subjects: 974
Study: 33827837

Group type: EXPERIMENTAL
Intervention: PACT plus treatment as usual (TAU)
Number of subjects: 238

Group type: COMPARATOR
Intervention: TAU only
Number of subjects: 238
Study: 36495509

Group type: EXPERIMENTAL
Intervention: High NT-proBNP group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Low NT-proBNP group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Patients with left ventricular hypertrophy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Patients without left ventricular hypertrophy
Number of subjects: 100
Study: 34373019

Group type: EXPERIMENTAL
Intervention: Cryopreservation (CP) method
Number of subjects: 143

Group type: COMPARATOR
Intervention: Subcutaneous pocket (SP) method
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Age of participants in post-operative infection group
Number of subjects: 143
Study: 32803895

Group type: EXPERIMENTAL
Intervention: Mind over Matter (MOM) workshop
Number of subjects: 6
Study: 34467402

Group type: EXPERIMENTAL
Intervention: Fostamatinib
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 33317922

Group type: EXPERIMENTAL
Intervention: Mutations in exon 4 or 7 of TP53
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Other TP53 mutations
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Wild-type TP53
Number of subjects: 195
Study: 36008838

Group type: COMPARATOR
Intervention: sarilumab + methotrexate (MOBILITY)
Number of subjects: 2112

Group type: COMPARATOR
Intervention: sarilumab + conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) (TARGET)
Number of subjects: 2112

Group type: COMPARATOR
Intervention: sarilumab (MONARCH)
Number of subjects: 2112

Group type: COMPARATOR
Intervention: adalimumab (MONARCH)
Number of subjects: 2112

Group type: EXPERIMENTAL
Intervention: sarilumab (both combination and monotherapy)
Number of subjects: 2112
Study: 34469763

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 3625

Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 3625
Study: 32818264

Group type: EXPERIMENTAL
Intervention: IDA alone
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: IDA combined with AZI
Number of subjects: 37

Group type: COMPARATOR
Intervention: AZI alone
Number of subjects: 37
Study: 35501156

Group type: EXPERIMENTAL
Intervention: 2.5 mg haloperidol
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 34860673

Group type: EXPERIMENTAL
Intervention: app-delivered Mindfulness Training (MT)
Number of subjects: 65

Group type: COMPARATOR
Intervention: treatment as usual (control)
Number of subjects: 65
Study: 34048362

Group type: EXPERIMENTAL
Intervention: Automated prompts to clinical staff to invite patients to NHSHC
Number of subjects: 7564

Group type: COMPARATOR
Intervention: No Prompt to clinical staff
Number of subjects: 7564
Study: 32063462

Group type: EXPERIMENTAL
Intervention: Pharmacological preventive potential for positive AAA screening
Number of subjects: 25074

Group type: EXPERIMENTAL
Intervention: Pharmacological preventive potential for positive PAD screening
Number of subjects: 25074

Group type: EXPERIMENTAL
Intervention: Pharmacological preventive potential for combined vascular screening
Number of subjects: 25074

Group type: EXPERIMENTAL
Intervention: Attendance at vascular screening
Number of subjects: 25074
Study: 35677463

Group type: EXPERIMENTAL
Intervention: MRI imaging with a 1.5 TMR scanner and knee joint standard array coil imaging
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (31 outpatients with acute knee joint injury of the same age group)
Number of subjects: 31
Study: 34479242

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (50 mg/kg/single dose)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Aminophylline (5 mg/kg/dose followed by continuous infusion at 1 mg/kg/hour for 3 hours)
Number of subjects: 131
Study: 35920480

Group type: EXPERIMENTAL
Intervention: Flower essences
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study: 36621408

Group type: EXPERIMENTAL
Intervention: MenACWY-TT at Month 0 (ACWY1d)
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: MenACWY-TT at Months 0 and 2 (ACWY2d)
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: MenACWY-TT and PCV13 at Month 0 (Co-Ad)
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: PCV13 at Month 0 and MenACWY-TT at Month 2 (PCV13/ACWY)
Number of subjects: 802

Group type: COMPARATOR
Intervention: MenACWY-TT (1 dose)
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: MenACWY-TT (2 doses)
Number of subjects: 802
Study: 32966587

Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34